For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a significant change. These innovative therapies protect the transthyretin protein, preventing its damaging build-up and reducing the impact of the il